Agilent Expands Cell Analysis R&D Capabilities in Ireland

Technologies Inc. (NYSE: A) today announced the opening of a new,
purpose-built extension to its Little Island, Cork facility in Ireland.
The campus will focus on developing advanced technologies for the
analysis of live-cells in real-time.

The expanded state-of-the-art facility incorporates recently acquired
Luxcel Biosciences, adding real-time, fluorescence plate reader-based in
cell assay kits to Agilenta??s cell analysis portfolio. The
complex will house two new laboratories, one dedicated to cell analysis
technologies, and the other to develop biosensors and related bio assay

Agilent entered the cell analysis market in 2015 with the acquisition of
Seahorse Bioscience, a leader in the development of specialized
instruments and live-cell, kinetic assays. The addition of Luxcel
expands Agilent's cell analysis portfolio and brings new capabilities
through technology and research which will drive advancements in this
fast-evolving field for Agilent globally.

"Technological progression allowing researchers to examine cell health
and function kinetically, and in real-time, are driving global demand
for complete cell analysis solutions,a?? said Todd Christian, general
manager, Agilent Cell Analysis Division. "The Luxcel acquisition and
Agilent Ireland expansion underscore Agilenta??s continued commitment to
the growing cell analysis market.a??

"Wea??re excited that Agilent has invested in Ireland,a?? said Martin
Shanahan, chief executive officer, IDA Ireland. "Luxcel has partnerships
and active research programs in Ireland, and with major EU and UK
research institutions. This expansion will not only provide the most
up-to-date and advanced solutions for Agilenta??s customers but will have
a significant positive impact within the Irish and European innovation
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Март 2021    »